first reported that miR145-5p acts as a tumor suppressor in a variety of tumors, including breast cancer (30); subsequently, miR-145-5p was shown to modulate immune response by targeting the 3’-untranslated region of Toll-like receptor 4 (31), and to increase epithelial-mesenchymal transition through the control of N-cadherin, vimentin and E-cadherin protein expression levels (32). This evidence concerns the gene CDH1 and breast carcinoma.